Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page
Price
Target price
€87.55

€87.55

2.150%
0.35
2.150%
€93.50

€93.50

 
Latest predictions
€100.00
13.07.20
buy
€87.00
10.12.19
buy
Your prediction

Ipsen S.A. Stock

Ipsen S.A. gained 2.150% today.
The community is currently still undecided about Ipsen S.A. with 2 Buy predictions and 0 Sell predictions.
With a target price of €93.00 there is a slightly positive potential of 6.225% for Ipsen S.A. compared to the current price of €87.55.

Pros and Cons of Ipsen S.A. in the next few years

Pros
?
Future proof business model
?
Brand
?
Non-cyclic/Cyclic
Cons
?
Growth compared to competition
?
Conscious of the environment
?
Market Position
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Published 10.12.19
Prediction Buy
Perf. (%) 10.688%
Target price 87.000
Change

Buy with target price 87.0

Published 27.03.12
Prediction Buy
Perf. (%) 6.570%
Target price 21.000
Change

(Zielkurs erreicht)

Published 01.03.12
Prediction Buy
Perf. (%) 6.570%
Target price 21.000
Change

Kauf für Rebound

Die Ergebnisse sind in und der Preis ist gesunken, aber der Wert überverkauft ist und wird daher bald steigen.

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about Ipsen S.A. Stock

New thread Forum

News

Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer


Ipsen (Euronext: IPN; ADR: IPSEY), today announced the primary analysis of the Phase I/II study evaluating the investigational use of irinotecan liposome injection (Onivyde®) in combination with

Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy


Regulatory News:



Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabozantinib) versus Stivarga® (regorafenib) for

Ipsen Provides Update on Palovarotene Clinical Programs


Regulatory News:



Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will begin to reinitiate palovarotene dosing in patients 14 years of age and older currently participating in its